Denemek ALTIN - Özgür

BioSpectrum Asia - BioSpectrum Asia Feb 2024

filled-star
BioSpectrum Asia

Magzter GOLD ile Sınırsız Olun

Okumak BioSpectrum Asia sadece bir abonelikle 9.000'den fazla diğer dergi ve gazeteyle birlikte  

Kataloğu Görüntüle

1 Ay

$14.99

1 Yıl

$149.99

$12/month

(OR)

Yalnızca BioSpectrum Asia dergisine abone olun

Bu sayıyı satın alın: BioSpectrum Asia Feb 2024

undefined sayı BioSpectrum Asia Feb 2024 tarihinden itibaren başlıyor

12 sayı BioSpectrum Asia Feb 2024 tarihinden itibaren başlıyor

Bu sayıyı satın al

$0.99

1 Yıl

$10.99

Please choose your subscription plan

İstediğiniz zaman iptal edebilirsiniz.

(Hiçbir Taahhüt Yok) ⓘ

Abonelikten memnun kalmazsanız, aboneliğin başlangıç tarihinden itibaren 7 gün içinde help@magzter.com adresine e-posta göndererek tam para iadesi alabilirsiniz. Soru sorulmaz - Söz veriyoruz! (Not: Tek sayı satın alımları için geçerli değildir)

Dijital Abonelik

Anında Erişim ⓘ

Magzter web sitesi, iOS, Android ve Amazon uygulamalarında anında okumaya başlamak için hemen abone olun.

Doğrulanmış Güvenli

ödeme ⓘ

Magzter, doğrulanmış bir Authorize.Net satıcısıdır. Daha Fazla Bilgi Edinin

Bu sayıda

Next-Gen ADCs as Precision Weapon Against Cancer Antibody-Drug Conjugates (ADCs) are emerging as a crucial frontier in targeted cancer care. Although the first ADC was approved in 2000, the space has experienced a renaissance in recent times. Major pharmaceutical players like Novartis and Pfizer, including startups, are announcing deals in this space almost every day. Within the Asia-Pacific (APAC) region, China stands at the forefront of ADC drug development. GlobalData reports that numerous domestic companies in China are actively shifting their focus towards the creation of pioneering ADC-based treatment options, particularly for solid tumours like breast, gastric, and bladder cancer. When we observe World Cancer Day on February 4, we explore the promising world of next-gen ADCs, exploring advancements and unravelling the advantages they offer compared to other therapies like cell and gene therapies.

BioSpectrum Asia Description:

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.

* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.

* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.

* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.

* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.

İlgili Başlıklar

Popüler Kategoriler